The HER2 protein is overexpressed in 10-40% of human breast tumors. Overexpression is often the result of gene amplification and is associated with poor prognosis in breast cancer patients. Patients with overexpression are eligible for therapy with the monoclonal antibody trastuzumab, commercially known as Herceptin®, which may be used as a treatment in HER2 amplified breast cancer.
